AxoGen, Inc.

NASDAQ:AXGN

Medical - Devices

Healthcare
$56.95 +0.56%

+$0.25 today

Market cap
$3.40B
Beta
1.12
P/E (TTM)
-73.4
EPS (TTM)
-$0.61
52W Low $9.35High $45.83

Volume 2.11M

Average 1.08M

AXGN Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

AxoGen, Inc.NASDAQ: AXGN

Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Free cash flow growth accelerates

Q3 FY2026 free cash flow of $15.14M rose 1015.2% year over year, ahead of the +471.7% change in trailing-twelve-month free cash flow. Sequentially, it rose 2419.8% from the prior quarter. Over 3 fiscal years it compounded at -57.2% a year.

Context

  • Free cash flow amounted to 1.3% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Free cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1015.2% holds above the trailing-twelve-month pace of +471.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$15.14M+2419.8% QoQ
Last fiscal yearDec 2025
-$2.93M-26763.6% YoY
LTMSep 2026
$16.31M+471.7% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1015.2%——
1 year-26763.6%——
3-year CAGR-57.2%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(2.93M) USD
Year-over-year change
-26763.6%

Free Cash Flow vs competitors

How AXGN compares with its peers on the latest reported figures

  • AXGN's LTM Sep 2026 free cash flow of $16.31M is the 5th largest of the 7 companies compared; the peer median is $531.38K.
  • Its year-over-year change of +471.7% is the highest of 7, against a peer median of +6.1%.
  • Free cash flow amounts to 6.1% of revenue for AXGN, versus a peer median of 16.8%.
AXGN Competitors Peer median
Free Cash Flow for AXGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HUMAHumacyte, Inc.LTM Mar 2026$102.38M +1.6%+13.6%5078.2%
MDXGMiMedx Group, Inc.LTM Mar 2026$65.5M +10.6%—16.8%
TELATELA Bio, Inc.LTM Jun 2026$31.62M -8.8%-12.4%39.6%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$17.08M +344.0%+39.4%3.3%
AXGNAxoGen, Inc.LTM Sep 2026$16.31M +471.7%-57.2%6.1%
BSEMBioStem Technologies, Inc.LTM Jun 2026$8.83M -133.5%——
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$7.77M +182.7%—6.4%
Peer median (excluding AXGN) $531.38K+6.1%+13.6%16.8%

Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.99M)(28.95M)(21.72M)(9.96M)(15.7M)
Depreciation & Amortization4.74M4.85M5.55M7.84M8.19M
Deferred Income Tax3.37M0000
Stock-Based Compensation10.92M15.59M14.42M15.91M30.11M
Change in Working Capital(6.28M)(9.56M)(4.39M)(10.04M)(24.62M)
Accounts Receivables(499K)(4.64M)(2.69M)392K(2.46M)
Inventory(7.48M)(3.66M)(6.05M)(10.16M)(9.19M)
Accounts Payables(270K)660K6.51M125K(7.16M)
Other Working Capital1.97M(1.93M)(2.15M)(399K)(5.81M)
Other Non-Cash Items831K2M415K797K2.83M
Operating Cash Flow(13.41M)(16.07M)(5.72M)4.54M812K
Capital Expenditures(28.4M)(21.25M)(14.92M)(4.52M)(3.75M)
Acquisitions (Net)(589K)3.2M000
Purchases of Investments(68.7M)(39.25M)(10.2M)(5.77M)(13.72M)
Sales of Investments72.5M57.3M44.37M014M
Other Investing Activities1.54M(3.2M)(1.05M)(1.42M)(1.85M)
Investing Cash Flow(23.65M)(3.2M)19.25M(10.3M)(5.32M)
Debt Repayment14.99M(12K)(10K)(10K)(32K)
Common Stock Issued5.47M1.81M1.96M2.3M10.53M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow20.45M1.79M1.95M2.29M10.5M
Effect of Forex Changes00000
Net Change in Cash(16.6M)(17.47M)15.49M(3.47M)5.99M
Free Cash Flow(41.81M)(37.32M)(20.63M)11K(2.93M)

AxoGen, Inc.

NASDAQ:AXGN

Intrinsic Alpha fair value

Locked

Current Price

$56.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.